Sugi Predict

Sugi Predict / Compounds / SCHEMBL2525367

SCHEMBL2525367

SCHEMBL2525367

C#C[C@]1(CO)O[C@@H](n2cnc3c(N)ncnc32)CC1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC28A1 O00337 2/20 0.53
▸ SLC28A2 O43868 2/20 0.53
▸ ADA P00813 1/20 0.50
▸ AHCY P23526 6/20 0.48
▸ ADORA3 P0DMS8 3/20 0.48
▸ ADORA2A P29274 3/20 0.48
▸ ADORA2B P29275 2/20 0.48
▸ PRMT5 O14744 1/20 0.48
▸ WDR77 Q9BQA1 1/20 0.48
▸ MAPK1 P28482 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ PI4KA P42356 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ PI4K2B Q8TCG2 2/20 0.46
▸ PI4K2A Q9BTU6 2/20 0.46
▸ PI4KB Q9UBF8 2/20 0.46
▸ TP53 P04637 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18670634 1.00 SLC28A1 (0.53) SLC28A1SLC28A2ADAAHCYADORA3
SCHEMBL31652753 1.00 SLC28A1 (0.53) SLC28A1SLC28A2ADAAHCYADORA3
SCHEMBL2525364 1.00 SLC28A1 (0.53) SLC28A1SLC28A2ADAAHCYADORA3
SCHEMBL29654853 1.00 SLC28A1 (0.53) SLC28A1SLC28A2ADAAHCYADORA3
SCHEMBL9548815 0.89 SLC28A1 (0.53) SLC28A1SLC28A2ADAAHCYADORA3
SCHEMBL9548828 0.89 SLC28A1 (0.53) SLC28A1SLC28A2ADAAHCYADORA3
SCHEMBL26129640 0.88 HIF1A (0.39) SLC28A1SLC28A2ADAAHCYADORA3
SCHEMBL7211347 0.88 HIF1A (0.39) SLC28A1SLC28A2ADAAHCYADORA3
SCHEMBL7211350 0.88 HIF1A (0.39) SLC28A1SLC28A2ADAAHCYADORA3
SCHEMBL2524218 0.86 AHCY (0.49) SLC28A1SLC28A2AHCYADORA3TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1177202-B1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORP (JP) 2003-09-24 — — EP claimed
US-6333315-B1 FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-12-25 — — US claimed
US-8039614-B2 4' -C-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2011-10-18 — — US disclosed
US-7625877-B2 4′-c-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2009-12-01 — — US disclosed
US-20090234110-A1 4' -C-substituted-2-haloadenosine derivative KOHGO SATORU 2009-09-17 — — US disclosed
US-20080153774-A1 Acquired Immune Deficiency Syndrome (AIDS); 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine; anti-HIV activity, particularly against a multi-drug-resistant HIV strain; less cytotoxicity, exhibit resistance to inactivation by adenosine deaminase KOHGO SATORU 2008-06-26 — — US disclosed
EP-1589026-B1 4'-C-Substituted-2-Haloadenosine derivative YAMASA CORP (JP) 2008-03-12 — — EP disclosed
US-7339053-B2 4′-C-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2008-03-04 — — US disclosed
EP-1589026-A1 4'-C-Substituted-2-Haloadenosine derivative YAMASA CORPORATION (JP) 2005-10-26 — — EP disclosed
US-20050215512-A1 4' -C-substituted-2-haloadenosine derivative YAMASA CORPORATION (JP) 2005-09-29 — — US disclosed
EP-1177202-B1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORP (JP) 2003-09-24 — — EP disclosed
US-6403568-B1 FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) YAMASA CORPORATION (JP) 2002-06-11 — — US disclosed
US-20020022722-A1 4'-C-ethynyl pyrimidine nucleoside compounds OHRUI HIROSHI (JP) 2002-02-21 — — US disclosed
EP-1177202-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 — — EP disclosed
US-6333315-B1 FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-12-25 — — US disclosed
US-6291670-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-09-18 — — US disclosed
WO-2000069877-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022722-A1 4'-C-ethynyl pyrimidine nucleoside compounds PNP, TYMP, NUDT1 SLC28A1 26/4885SLC28A2 50/4885ADA 31/4885
US-20080153774-A1 Acquired Immune Deficiency Syndrome (AIDS); 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine; anti-HIV activity, particularly against a multi-drug-resistant HIV strain; less cytotoxicity, exhibit resistance to inactivation by adenosine deaminase ADA, PNP, DCTD SLC28A1 79/4885SLC28A2 86/4885ADA 1/4885
US-20050215512-A1 4' -C-substituted-2-haloadenosine derivative ADORA1, ADORA2A, ADORA3 SLC28A1 11/4885SLC28A2 12/4885ADA 16/4885
US-20090234110-A1 4' -C-substituted-2-haloadenosine derivative ADORA1, ADORA2A, ADORA3 SLC28A1 89/4885SLC28A2 92/4885ADA 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.